[Discussion] gastric emptying is doing more work than we give it credit for
gastric emptying is doing more work than we give it credit for. I have gone back and forth on this for months.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
receptor distribution is why the side effects are where they are
Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
Yes. The central component is the one that explains the reports on this site better than gastric emptying does.
Does the effect persist with continued dosing or does tolerance develop?
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.
read the discussion section, that is where the honesty lives
Are we talking about receptor affinity or clinical potency?
glucagon agonism sounds paradoxical until you read the energy expenditure work
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
That conflates receptor affinity with clinical potency. They are related and they are not the same thing.
- 1receptor distribution is why the side effects are where they are7 comments in this branch · started by u/slow_logbook